BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 23864164)

  • 1. Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro.
    Burmakin M; Shi Y; Hedström E; Kogner P; Selivanova G
    Clin Cancer Res; 2013 Sep; 19(18):5092-103. PubMed ID: 23864164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
    Van Maerken T; Ferdinande L; Taildeman J; Lambertz I; Yigit N; Vercruysse L; Rihani A; Michaelis M; Cinatl J; Cuvelier CA; Marine JC; De Paepe A; Bracke M; Speleman F; Vandesompele J
    J Natl Cancer Inst; 2009 Nov; 101(22):1562-74. PubMed ID: 19903807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).
    Drakos E; Singh RR; Rassidakis GZ; Schlette E; Li J; Claret FX; Ford RJ; Vega F; Medeiros LJ
    Leukemia; 2011 May; 25(5):856-67. PubMed ID: 21394100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The MDM2 inhibitor CGM097 combined with the BET inhibitor OTX015 induces cell death and inhibits tumor growth in models of neuroblastoma.
    Maser T; Zagorski J; Kelly S; Ostrander A; Goodyke A; Nagulapally A; Bond J; Park Y; Saulnier Sholler G
    Cancer Med; 2020 Nov; 9(21):8144-8158. PubMed ID: 33034426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro.
    Wang J; Zheng T; Chen X; Song X; Meng X; Bhatta N; Pan S; Jiang H; Liu L
    J Gastroenterol Hepatol; 2011 Feb; 26(2):371-7. PubMed ID: 21261729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy.
    Moreno-Smith M; Lakoma A; Chen Z; Tao L; Scorsone KA; Schild L; Aviles-Padilla K; Nikzad R; Zhang Y; Chakraborty R; Molenaar JJ; Vasudevan SA; Sheehan V; Kim ES; Paust S; Shohet JM; Barbieri E
    Clin Cancer Res; 2017 Nov; 23(21):6629-6639. PubMed ID: 28821555
    [No Abstract]   [Full Text] [Related]  

  • 7. Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma.
    Lu J; Guan S; Zhao Y; Yu Y; Wang Y; Shi Y; Mao X; Yang KL; Sun W; Xu X; Yi JS; Yang T; Yang J; Nuchtern JG
    Oncotarget; 2016 Dec; 7(50):82757-82769. PubMed ID: 27764791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
    Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
    Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Didymin induces apoptosis by inhibiting N-Myc and upregulating RKIP in neuroblastoma.
    Singhal J; Nagaprashantha LD; Vatsyayan R; Ashutosh ; Awasthi S; Singhal SS
    Cancer Prev Res (Phila); 2012 Mar; 5(3):473-83. PubMed ID: 22174364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
    Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L
    Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SCH529074, a small molecule activator of mutant p53, which binds p53 DNA binding domain (DBD), restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of wild type p53.
    Demma M; Maxwell E; Ramos R; Liang L; Li C; Hesk D; Rossman R; Mallams A; Doll R; Liu M; Seidel-Dugan C; Bishop WR; Dasmahapatra B
    J Biol Chem; 2010 Apr; 285(14):10198-212. PubMed ID: 20124408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RITA inhibits multiple myeloma cell growth through induction of p53-mediated caspase-dependent apoptosis and synergistically enhances nutlin-induced cytotoxic responses.
    Saha MN; Jiang H; Mukai A; Chang H
    Mol Cancer Ther; 2010 Nov; 9(11):3041-51. PubMed ID: 21062913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reactivation of p53 by novel MDM2 inhibitors: implications for pancreatic cancer therapy.
    Azmi AS; Philip PA; Aboukameel A; Wang Z; Banerjee S; Zafar SF; Goustin AS; Almhanna K; Yang D; Sarkar FH; Mohammad RM
    Curr Cancer Drug Targets; 2010 May; 10(3):319-31. PubMed ID: 20370686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas.
    Künkele A; De Preter K; Heukamp L; Thor T; Pajtler KW; Hartmann W; Mittelbronn M; Grotzer MA; Deubzer HE; Speleman F; Schramm A; Eggert A; Schulte JH
    Neuro Oncol; 2012 Jul; 14(7):859-69. PubMed ID: 22591662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors.
    Issaeva N; Bozko P; Enge M; Protopopova M; Verhoef LG; Masucci M; Pramanik A; Selivanova G
    Nat Med; 2004 Dec; 10(12):1321-8. PubMed ID: 15558054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The p53-reactivating small-molecule RITA enhances cisplatin-induced cytotoxicity and apoptosis in head and neck cancer.
    Roh JL; Ko JH; Moon SJ; Ryu CH; Choi JY; Koch WM
    Cancer Lett; 2012 Dec; 325(1):35-41. PubMed ID: 22634494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A natural small molecule harmine inhibits angiogenesis and suppresses tumour growth through activation of p53 in endothelial cells.
    Dai F; Chen Y; Song Y; Huang L; Zhai D; Dong Y; Lai L; Zhang T; Li D; Pang X; Liu M; Yi Z
    PLoS One; 2012; 7(12):e52162. PubMed ID: 23300602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097.
    Weisberg E; Halilovic E; Cooke VG; Nonami A; Ren T; Sanda T; Simkin I; Yuan J; Antonakos B; Barys L; Ito M; Stone R; Galinsky I; Cowens K; Nelson E; Sattler M; Jeay S; Wuerthner JU; McDonough SM; Wiesmann M; Griffin JD
    Mol Cancer Ther; 2015 Oct; 14(10):2249-59. PubMed ID: 26206331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma.
    Van Maerken T; Speleman F; Vermeulen J; Lambertz I; De Clercq S; De Smet E; Yigit N; Coppens V; Philippé J; De Paepe A; Marine JC; Vandesompele J
    Cancer Res; 2006 Oct; 66(19):9646-55. PubMed ID: 17018622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA.
    Zhao CY; Grinkevich VV; Nikulenkov F; Bao W; Selivanova G
    Cell Cycle; 2010 May; 9(9):1847-55. PubMed ID: 20436301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.